Brief: Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) In IgA Nephropathy
27/08/2025 22:15
Aug 27 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS ANNOUNCES U.S. FDA APPROVES REMS MODIFICATION FOR FILSPARI® (SPARSENTAN) IN IGA NEPHROPATHY Source text: ID:nBw2KXGB8a Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule